DOCSLIB.ORG

Non-FDA Approved Medications/Products Are Listed by NDC. This List Is Subject to Change

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Non-FDA Approved Medications/Products Are Listed by NDC. This List Is Subject to Change Non-FDA Approved Medication and Product List *Note: Non-FDA approved medications/products are listed by NDC. This list is subject to change. NDC Product Name Updated 3Q 2018 51927174200 VANCOMYCIN POW 45861006001 MEXILETINE POW HCL 49452615102 PYRIMETHAMIN POW 51927277100 NAPROXEN POW SODIUM 65044994006 BEE VENOM INJ 1300MCG 00517810525 ZINC SULFATE INJ 5MG/ML 51927247300 CEDAR LEAF OIL 60966068303 PENTOXIFYL POW 71019034113 SUCCINYLCHOL INJ 200/10ML 52372072202 DEXAMETHASON POW MICRONIZ 49452444006 L-MENTHOL CRY 62991409701 EMPTY CAPSUL CAP SIZE 3 38779296900 L-5-METHYLTE POW HYDROFOL 51927131900 BASIC FUCHSI POW HCL 71019013833 BUPIVAC/NACL INJ 0.25-0.9 52372082601 CAPSULE LOCK CAP #1 CLEAR 63807010035 SALINE FLUSH INJ 0.9% 52372090901 BACLOFEN POW 63275999308 BUPIVACAINE POW HCL 71019020511 NEOSTIG METH INJ 5MG/5ML 38779068703 MELATONIN POW 62991256105 METHYLCOBALA POW 65694010010 NALTREXONE TAB 50MG 60592004611 L-CARNITINE POW 49452362004 HYDROQUINONE POW 00395804935 BENZOCAINE POW 60592004111 CYCLOBENZAPR POW HCL 38779048806 CAPTOPRIL POW 51927103900 SUCROSE POW 38779023905 MICONAZOLE POW 49452920103 LEVORPHANOL POW TARTRATE 58597801904 LIDOCAINE POW 49452321501 FUMARIC ACID POW 62991130004 MELATONIN POW 64253033330 HEPARIN LOCK INJ 100/ML 38779111501 CAPSULE CONI CAP -SNAP #1 49452132002 CAFFEINE POW ANHYDROU 51552148507 LOLLIPOP MIS BASE 49430000505 CYCLOBENZAPR POW 38779103001 BENZYL BENZO LIQ 51927146300 BHT POW 38779297008 CREATINE POW ANHYDROU 51927490000 CALCIUM GLUC POW MONOHYDR 51927442600 PIMOBENDAN POW 13811010110 HYOSCYAMINE TAB 0.125MG 37803023406 LEVOCETIRIZI POW DHCL 00276020130 ZAVARA CAP 1MG-5750 60592031111 HYDROXYPROG POW CAPROATE 61553041041 MAG SULF/D5W INJ 1GM/50ML 49452454505 METFORMIN POW HCL 49452026004 ALLANTOIN POW 08573054520 HYDRFRA BLUE PAD RDY 4X5" 52372064802 SODIUM POW BICARBON 59353000301 RETACRIT INJ 3000UNIT 58597854908 THIAMINE HCL POW 51927451700 XANTHAN GUM POW 62991149705 NIACINAMIDE POW 52372065801 CAPSULE LOCK CAP #00 CLR 38779191308 SOD BROMIDE GRA 60966042401 BACLOFEN POW 51552008003 SODIUM MIS HYDROXID 71092999902 NIFEDIPINE POW 52747050230 FUSION PLUS CAP 60966043101 PIROXICAM POW 38779054804 NAPROXEN POW 13478000304 XOLEGEL DUO/ KIT XOLEX 38779013668 JUNIPER TAR OIL 51552024405 SULFACET SOD POW 52372061801 OMEGA-3 DHA POW 49452481003 NAPHAZOLINE POW HCL 71019010309 GLYCOPYRROLA INJ 1MG/5ML 70350781802 GLUTAMINE POW 63807050512 HEPARIN LOCK INJ 10UNT/ML 61553035328 MORPHIN/NACL INJ 2MG/2ML 58980091895 LACTIC ACID LOT 10% 51552135305 ORPHENADRINE POW CITRATE 63275989208 SILDENAFIL POW CITRATE 52372069804 METFORMIN POW HCL 10135059510 CYCLOBENZAPR TAB 10MG 49452322203 FUROSEMIDE POW 38779010103 UREA POW 61553085641 MORPHINE SOL 50/50ML 71092999804 TRAMADOL HCL POW 52372077503 MILK THISTLE POW EXTRACT 00395806362 PROGESTERONE POW MICRONIZ 51552136901 L-METHYLFOLA POW CALCIUM 38779003482 NEOMYCIN POW SULFATE 49452366404 IMIDUREA POW 58552012402 CARBAPHEN 12 SUS PED 62991307801 ITRACONAZOLE POW 51927292400 DIETHYLCARB POW CITRATE 52372062902 ZINC ACETATE POW 49452214702 CLONIDINE POW 70457991403 METHOCEL E4M POW 63323002605 SOD BICARB INJ 4.2% 58980047310 MELPAQUE HP CRE 4% 62991110401 MICONAZOLE POW NITRATE 00395266175 SIMPLE SYP 62991252202 VANCOMYCIN POW 49452606002 PROGESTERONE POW MICRONIZ 51552147102 FLUOXETINE POW HCL 10144092801 QUTENZA KIT 8% 1-PCH 51927428000 GLUCOSAMINE POW SUL NACL 38779022404 FOLIC ACID POW 49452457303 METHIMAZOLE POW 49452358005 HYDROCORT POW 51862013501 POT CHLORIDE POW 20MEQ 38779061401 DIMETHYL SOL SULFOXID 63275992109 PROGESTERONE POW WETTABLE 60966052202 FLUCONAZOLE POW 61553031265 PHENYLEPHRIN SOL 40MCG/ML 10481100201 ANACAINE OIN 00338960824 SOD CHLORIDE INJ 0.9% 60966042301 GABAPENTIN POW 51552041804 FOLIC ACID POW 62991136702 SILICA GEL 45861002205 BACLOFEN POW 45861010301 CYCLOBENZAPR CRE 5% KIT 51927371100 CHRYSADERM CRE NIGHT 49452768001 TETRACAINE POW HCL 71019020601 NICARDIPINE INJ NACL 52187052510 XALIX SOL 28% 51552137603 SUMATRIPTAN POW SUCCINAT 61553042802 MAG SULF/LAC INJ 20/250ML 70457998202 VITAMIN E POW ACETATE 62991108702 KETAMINE HCL POW 00395600181 HRT BASE CRE BOTANICA 49452508001 PENTOXIFYL POW 38779260405 UBIQUINOL POW 52372090503 CETYL MYRIST POW OLEATE 71019035201 VANCOMY/NACL INJ 1.5/250 62991260405 MITOTANE POW 62991309302 POVIDONE POW K-30 51927243300 ALKYL BENZOA LIQ C12-15 38779223308 PREGNENOLONE POW MICRONIZ 75839006410 VANCOMYCIN POW 38779007208 DEXTROSE POW ANHYDROU 62991290903 PYRIMETHAMIN POW 49452481703 NAPROXEN POW SODIUM 54288123002 TETRACYCLINE POW 00409660902 NEUT INJ 4% 61534810008 BAL SALT SOL OP 62991113301 RIFAMPIN POW 49452460305 METHOXSALEN CRY USP/NF 71092997102 METHYLCOBALA POW 38779279408 TRANEXAMIC POW ACID 38779004345 DOXYCYCLINE POW HYCLATE 62991278503 NYSTATIN POW 58597804904 ESTRONE POW 49452739803 NA ASCORBATE POW 49452362502 HYDROXYCHLOR POW SULFATE 71019017011 LIDOCAIN HCL INJ 10MG/ML 49452312002 FE GLUCONATE POW USP NF 49452605002 PROCAINE HCL CRY 51927477200 TAZAROTENE POW 62991115103 TAMOXIFEN POW CITRATE 42799010501 METHENAM MAN TAB 500MG 49452107701 BETAMETHASON POW SOD PHOS 38779288302 AMITRIPTYLIN POW HCL 38779092205 BUTALBITAL POW 49452618002 QUINIDINE CRY SULFATE 51552030403 AMPHOTERICIN POW B 49452210003 CITRIC ACID POW ANHYDROU 52372085601 NIFEDIPINE POW 50114701501 ENGYSTOL INJ 51552002504 DEXAMETH SOD POW PHOSPHAT 62991103904 CYANOCOBAL POW 52372062502 GLUCOSAMINE POW ACETYL-D 61553012802 FENT/BUPIVAC INJ /NACL 62991138407 LACTOSE POW MONOHYDR 62991217507 TRIAMCINOLON POW DIACETAT 15455001306 METHOCARBAM POW 71019020503 NEOSTIG METH INJ 3MG/3ML 52372066303 CLOTRIMAZOLE POW 08065183085 PROVISC INJ 1% 51927354900 ETHYL OLEATE LIQ 49452597102 PRALIDOXIME POW CHLORIDE 76439036290 L-METHYL- TAB B6-B12 38779062205 SOD LAURYL POW SULFATE 54288120210 GABAPENTIN POW 38779003896 CANTHARIDIN POW 13478000307 XOLEGEL DUO/ KIT HEAD&SHD 52372686803 PAPAVERINE POW HCL 52372065903 DILTIAZEM POW 38779005458 EDTA DISODIU POW USP 62991251702 ACETAZOLAMID POW 62991101305 BACLOFEN POW 51552153105 TESTOSTERONE POW MICRONIZ 60592050410 METRONIDAZOL POW BENZOATE 49452364002 HYDROXYETHYL POW CELLULOS 62991412001 EMPTY CAPSUL CAP SIZE 00 49452687002 NA MONOFLUOR POW PHOSPHAT 38779293404 BETAHISTINE POW HCL 51552046304 TETRACYCLINE POW 51552153302 BACLOFEN POW 70457990801 PHENYTOIN POW 51927916900 CARISOPRODOL POW 62991276902 ENALAPRIL POW MALEATE 15455951501 FLUCONAZOLE POW 71092995702 TADALAFIL POW 51552082103 BUSPIRONE POW HCL 38779297408 NICOTINAMIDE POW ADENINE 00299383906 ROSANIL EMU CLEANSER 38779253205 SPG SUPPOSI- MIS BASE 51927496000 RDT-PLUS POW 60966078202 PHENYTOIN POW 42192051030 PE/GUAIFENES DRO 1.5-20MG 52372065601 MISOPROSTOL POW HPMC 1% 58597808004 ANASTROZOLE POW 38779015003 PREDNISOLONE POW ANHYDROU 00395602059 RECURA CRE 40565012203 ACTICOAT 7 PAD 2"X2" 49452574205 POTASSIUM CRY BROMIDE 62942010112 DEBACTEROL SOL 30-50% 51552007809 CHLORHEX GLU SOL 20% 38779003708 MINERAL OIL LIGHT 38779000054 CLINDAMYCIN POW USP 62991203502 HYDROXYZINE POW HCL 13811006610 CORVITA 150 TAB 58597847208 PROGESTERONE POW MICRONIZ 52372086102 THIOSULFATE POW SODIUM 60592070545 SOD CHLORIDE GRA 38779181609 THEOPHYLLINE POW ANHYDROU 71850180601 BENZ PER- HC LOT 5-0.5% 71019035005 VANCOMY/NACL INJ 1.25/250 51991081090 METAFOLBIC TAB 71019037301 VECURON/NACL INJ 100/100 62991412007 EMPTY CAPSUL CAP SIZE 00 50114820001 LYMPHOMYSOT INJ X 38779103007 BENZYL BENZO LIQ 62991292902 SOD ACETATE POW TRIHYDRA 62991307102 POLYMYXIN B POW SULFATE 62991281202 PILOCARPINE POW NITRATE 38779005103 TRIAMCINOLON POW 51552014707 PROMETHAZINE POW HCL 49452002903 HYDROMORPHON POW HCL 63275991109 VERAPAMIL POW 00395804737 TETRACYCLINE POW 49452763102 TERBUTALINE POW SULFATE 38779009508 SACCHARIN POW SODIUM 38779000595 PYRANTEL POW PAMOATE 49452621703 RESERPINE POW 52372731501 GLUTATHIONE POW REDUCED 70324055103 SOD CHLORIDE INJ 0.9% 54288121401 ITRACONAZOLE POW 38779064109 CHLORAL CRY HYDRATE 38779007106 DEXAMETH SOD POW PHOSPHAT 51525011501 HYOSCYAMINE TAB 0.375 ER 00395262501 SALICYLIC POW ACID 00178062094 OVACE PLUS LOT 9.8% 63807016011 SOD CHLORIDE INJ 0.9% 38779292205 GLUCOSAMINE POW ACETYL-D 71019014109 BUPIVACAINE INJ 0.5% 42783066360 BENZODOX 60 MIS 69621082100 ZEYOCAINE KIT 5% 62991284103 ALUMINUM POW HYDROXID 62991294202 TRIMETHOBENZ POW HCL 38779014601 METRONIDAZOL POW 38779091001 CASTOR OIL 38779295709 TINIDAZOLE POW 00409158411 SOD CHLORIDE INJ 0.9% 51552027601 SPIRONOLACT POW 38779250705 IODOFORM POW 42291024501 DONNATAL TAB 16.2MG 70457991303 METHOCEL POW K100M 38779028005 NIFEDIPINE POW 76420004940 ESTRIOL POW MICRONIZ 61553094804 HEPARIN/NACL INJ 6000/L 38779309705 BUDESONIDE POW 69482019796 HYLATOPIC AER PLUS 10695009802 SIROLIMUS POW 71019032307 ROPIVAC/NACL INJ 0.1-0.9% 38779095809 ACETYL-L-CAR POW HCL 00395803543 DIPHENHYDRAM POW HCL 62991128201 HYDROXYETHYL POW CELLULOS 00395805619 KETOPROFEN POW 51552143805 AMLODIPINE POW BESYLATE 52372066003 SUCRALFATE POW 38779094700 LECITHIN GRA 51991018211 FERROCITE TAB PLUS 38779002375 MECLOFEN SOD POW 38779073807 MEDIDERM CRE 71092997805 ESTRADIOL POW MICRONIZ 52372064503 KOJIC ACID POW 62991101104 ASCORBIC ACD POW 38779056608 TETRACAINE POW HCL 00517390025 CALCIUM GLUC INJ 10% 38779297702 BANANA LIQ FLAVOR 24854030120 KERAGEL GEL WOUND 38779008327 ISOPROPYL LIQ PALMITAT 38779017808 LEUCOVORIN POW CALCIUM 51927227600 ACETAZOLAMID POW 62991201501 CAFFEINE POW ANHYDROU 44523060201 SOD SUL/SULF LOT 10-5% 51552049605 PHENTOLAMINE POW MESYLATE 49452792104 TRICHLORMETH POW 51927152400 TARTARIC ACD POW 49452466703 METHYLENE LIQ CHLORIDE 38779253504 ALPHA LIPOIC POW
Load more

Recommended publications
  • Steroid Recognition and Regulation of Hormone Action: Crystal
    Research Article 799 Steroid recognition and regulation of hormone action: crystal structure of testosterone and NADP+ bound to 3a-hydroxysteroid/ dihydrodiol dehydrogenase Melanie J Bennett1†, Ross H Albert1, Joseph M Jez1, Haiching Ma2, Trevor M Penning2 and Mitchell Lewis1* Background: Mammalian 3a-hydroxysteroid dehydrogenases (3a-HSDs) Addresses: 1Department of Biochemistry and modulate the activities of steroid hormones by reversibly reducing their C3 Biophysics, The Johnson Research Foundation, 37th and Hamilton Walk, Philadelphia, PA 19104- ketone groups. In steroid target tissues, 3a-HSDs act on 5a-dihydrotestosterone, 6059, USA and 2Department of Pharmacology, a potent male sex hormone (androgen) implicated in benign prostate hyperplasia University of Pennsylvania School of Medicine, 37th and prostate cancer. Rat liver 3a-HSD belongs to the aldo-keto reductase (AKR) and Hamilton Walk, Philadelphia, PA 19104-6084, superfamily and provides a model for mammalian 3a-, 17b- and 20a-HSDs, USA. which share > 65% sequence identity. The determination of the structure of 3a- †Present address: Division of Biology, California + HSD in complex with NADP and testosterone (a competitive inhibitor) will help Institute of Technology, 1200 E California Blvd., to further our understanding of steroid recognition and hormone regulation by Pasadena, CA 91125, USA. mammalian HSDs. *Corresponding author. E-mail: [email protected] Results: We have determined the 2.5 Å resolution crystal structure of recombinant rat liver 3a-HSD complexed with NADP+ and testosterone. The Key words: aldo-keto reductase, crystal structure, structure provides the first picture of an HSD ternary complex in the AKR 3a-hydroxysteroid/dihydrodiol dehydrogenase, superfamily, and is the only structure to date of testosterone bound to a protein.
    [Show full text]
  • Vasodilators for Primary Raynaud's Phenomenon
    Vasodilators for primary Raynaud's phenomenon Author Su, KYC, Sharma, M, Kim, HJ, Kaganov, E, Hughes, I, Abdeen, MH, Ng, JHK Published 2021 Journal Title Cochrane Database of Systematic Reviews Version Version of Record (VoR) DOI https://doi.org/10.1002/14651858.CD006687.pub4 Copyright Statement © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. This review is published as a Cochrane Review in the Cochrane Database of Systematic Reviews 2021, Issue 5. Art. No.: CD006687.. Cochrane Reviews are regularly updated as new evidence emerges and in response to comments and criticisms, and the Cochrane Database of Systematic Reviews should be consulted for the most recent version of the Review. Downloaded from http://hdl.handle.net/10072/405317 Griffith Research Online https://research-repository.griffith.edu.au Cochrane Library Cochrane Database of Systematic Reviews Vasodilators for primary Raynaud's phenomenon (Review) Su KYC, Sharma M, Kim HJ, Kaganov E, Hughes I, Abdeen MH, Ng JHK Su KYC, Sharma M, Kim HJ, Kaganov E, Hughes I, Abdeen MH, Ng JH. Vasodilators for primary Raynaud's phenomenon. Cochrane Database of Systematic Reviews 2021, Issue 5. Art. No.: CD006687. DOI: 10.1002/14651858.CD006687.pub4. www.cochranelibrary.com Vasodilators for primary Raynaud's phenomenon (Review) Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. Cochrane Trusted evidence. Informed decisions. Library Better health. Cochrane Database of Systematic Reviews T A B L E O F C O N T E N T S HEADER........................................................................................................................................................................................................
    [Show full text]
  • Current Status of Local Penile Therapy
    International Journal of Impotence Research (2002) 14, Suppl 1, S70–S81 ß 2002 Nature Publishing Group All rights reserved 0955-9930/02 $25.00 www.nature.com/ijir Current status of local penile therapy F Montorsi1*, A Salonia1, M Zanoni1, P Pompa1, A Cestari1, G Guazzoni1, L Barbieri1 and P Rigatti1 1Department of Urology, University Vita e Salute – San Raffaele, Milan, Italy Guidelines for management of patients with erectile dysfunction indicate that intraurethral and intracavernosal injection therapies represent the second-line treatment available. Efficacy of intracavernosal injections seems superior to that of the intraurethral delivery of drugs, and this may explain the current larger diffusion of the former modality. Safety of these two therapeutic options is well established; however, the attrition rate with these approaches is significant and most patients eventually drop out of treatment. Newer agents with better efficacy-safety profiles and using user-friendly devices for drug administration may potentially increase the long-term satisfaction rate achieved with these therapies. Topical therapy has the potential to become a first- line treatment for erectile dysfunction because it acts locally and is easy to use. At this time, however, the crossing of the barrier caused by the penile skin and tunica albuginea has limited the efficacy of the drugs used. International Journal of Impotence Research (2002) 14, Suppl 1, S70–S81. DOI: 10.1038= sj=ijir=3900808 Keywords: erectile dysfunction; local penile therapy; topical therapy; alprostadil Introduction second patient category might be represented by those requesting a fast response, which cannot be obtained by sildenafil; however, sublingual apomor- Management of patients with erectile dysfunction phine is characterized by a fast onset of action and has been recently grouped into three different may represent an effective solution for these 1 levels.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • PROVERA Medroxyprogesterone Acetate Tablets 2.5Mg, 5Mg, 10Mg, 100 Mg, 200 Mg Tablets
    PROVERA Medroxyprogesterone acetate tablets 2.5mg, 5mg, 10mg, 100 mg, 200 mg tablets What is in this leaflet establish a regular menstrual breast cancer or breast lumps cycle not diagnosed by your doctor This leaflet answers some common bleeding or discharge from questions about PROVERA. It does certain types of cancer including your nipples not contain all the available cancer of the breast, kidney and information. It does not take the endometrium (the lining of the miscarriage place of talking to your doctor or womb). pharmacist. cancer of the womb or ovary PROVERA, in combination with an uncontrolled high blood estrogen containing medicine, is All medicines have risks and pressure. benefits. Your doctor has weighed used to relieve symptoms of the risks of you taking PROVERA menopause in women with an intact Do not take PROVERA if you are against the benefits it is expected to uterus. This is called hormone pregnant or intend to become have for you. replacement therapy (HRT). pregnant. PROVERA is used to protect the If you have any concerns about lining of the uterus while the PROVERA may affect your taking this medicine, ask your estrogens relieve the symptoms of developing baby if you take it doctor or pharmacist. Keep this menopause. PROVERA is not during pregnancy. leaflet with your medicine. suitable as a HRT treatment in women who have undergone a Do not take PROVERA if the You may need to read it again. hysterectomy. packaging is torn or shows signs of tampering. Do not take Your doctor may have prescribed PROVERA after the expiry date What PROVERA is PROVERA for another purpose.
    [Show full text]
  • Liquid Spray Formulations for Buccal Delivery of Cannabinoids
    (19) TZZ_¥__T (11) EP 1 361 864 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 9/08 (2006.01) A61K 9/107 (2006.01) 04.12.2013 Bulletin 2013/49 A61K 36/185 (2006.01) (21) Application number: 02712063.3 (86) International application number: PCT/GB2002/000620 (22) Date of filing: 14.02.2002 (87) International publication number: WO 2002/064109 (22.08.2002 Gazette 2002/34) (54) LIQUID SPRAY FORMULATIONS FOR BUCCAL DELIVERY OF CANNABINOIDS FLÜSSIGE SPRAY FORMULIERUNGEN ZUR BUCCALEN VERABREICHUNG VON CANNABINOIDEN PREPARATIONS DE SPRAY LIQUIDE POUR L’ADMINISTRATION BUCCALE DE CANNABINOIDES (84) Designated Contracting States: (74) Representative: Schiller, Dominic Christopher et AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU al MC NL PT SE TR Harrison Goddard Foote LLP Designated Extension States: 4th Floor, Merchant Exchange RO SI 17-19 Whitworth Street West Manchester M1 5WG (GB) (30) Priority: 14.02.2001 GB 0103638 30.03.2001 US 280044 P (56) References cited: 05.04.2001 US 827158 WO-A-00/25127 WO-A-01/66089 11.05.2001 GB 0111597 WO-A-95/25504 WO-A1-02/32420 07.09.2001 GB 0121715 WO-A1-02/069993 US-A- 3 560 625 12.09.2001 US 951022 • EITAN ALHANATY; ET AL.: "Osmotic fragility of (43) Date of publication of application: liposomes as affected by antihemolytic 19.11.2003 Bulletin 2003/47 compounds" BIOCHIMICA ET BIOPHYSICA ACTA, vol. 339, no. 1, 1974, pages 146-155, (60) Divisional application: XP008008726 10180611.5 / 2 286 793 • PATRICIA S.
    [Show full text]
  • 268 Part 522—Implantation Or Injectable Dosage Form
    § 520.2645 21 CFR Ch. I (4–1–18 Edition) (ii) Indications for use. For the control 522.82 Aminopropazine. of American foulbrood (Paenibacillus 522.84 Beta-aminopropionitrile. larvae). 522.88 Amoxicillin. 522.90 Ampicillin injectable dosage forms. (iii) Limitations. The drug should be 522.90a Ampicillin trihydrate suspension. fed early in the spring or fall and con- 522.90b Ampicillin trihydrate powder for in- sumed by the bees before the main jection. honey flow begins, to avoid contamina- 522.90c Ampicillin sodium. tion of production honey. Complete 522.144 Arsenamide. treatments at least 4 weeks before 522.147 Atipamezole. main honey flow. 522.150 Azaperone. 522.161 Betamethasone. [40 FR 13838, Mar. 27, 1975, as amended at 50 522.163 Betamethasone dipropionate and FR 49841, Dec. 5, 1985; 59 FR 14365, Mar. 28, betamethasone sodium phosphate aque- 1994; 62 FR 39443, July 23, 1997; 68 FR 24879, ous suspension. May 9, 2003; 70 FR 69439, Nov. 16, 2005; 73 FR 522.167 Betamethasone sodium phosphate 76946, Dec. 18, 2008; 75 FR 76259, Dec. 8, 2010; and betamethasone acetate. 76 FR 59024, Sept. 23, 2011; 77 FR 29217, May 522.204 Boldenone. 17, 2012; 79 FR 37620, July 2, 2014; 79 FR 53136, 522.224 Bupivacaine. Sept. 8, 2014; 79 FR 64116, Oct. 28, 2014; 80 FR 522.230 Buprenorphine. 34278, June 16, 2015; 81 FR 48702, July 26, 2016] 522.234 Butamisole. 522.246 Butorphanol. § 520.2645 Tylvalosin. 522.275 N-Butylscopolammonium. 522.300 Carfentanil. (a) Specifications. Granules containing 522.304 Carprofen. 62.5 percent tylvalosin (w/w) as 522.311 Cefovecin.
    [Show full text]
  • New Directions for Erectile Dysfunction Therapies
    International Journal of Impotence Research (2002) 14, Suppl 1, S82–S92 ß 2002 Nature Publishing Group All rights reserved 0955-9930/02 $25.00 www.nature.com/ijir New directions for erectile dysfunction therapies K-E Andersson1* and P Hedlund1 1Department of Clinical Pharmacology, Lund University Hospital, S-22185, Lund, Sweden Research in the field of erectile function and dysfunction has continued to expand rapidly. Based on the information available, some directions for future erectile dysfunction therapies can be identified. The first direction is improvement of current therapeutic principles. A second generation of orally active phosphodiesterase (PDE) inhibitors is being introduced, and further developments within this field can be expected. The recent introduction of apomorphine has opened the way for new dopamine receptor agonists. The second direction is combinations of existing therapeutic principles. Combinations of apomorphine and sildenafil and apomorphine and a1-adrenoceptor (AR) antagonists, for example, seem attractive and may have a therapeutic potential in patients not responding satisfactorily to single-drug treatment. Nitrosylated a1-AR antagonists, combining nitric oxide donation and a1-ora2-AR antagonism, are currently being evaluated. The third direction is new targets within the central nervous system. Melanocortin receptor agonists have shown promise not only in animal models, but also in preliminary studies in humans. Other possible targets, such as growth hormone-releasing peptide receptors, are being explored. The fourth direction is new peripheral targets. Rho-kinase antagonism and non-nitric oxide-mediated stimulation of soluble guanylyl cyclase have been suggested as possible new principles for drug development. The fourth direction is gene therapy. Progress has been made in intracavernosal somatic gene therapy and will probably continue.
    [Show full text]
  • 01012100 Pure-Bred Horses 0 0 0 0 0 01012900 Lives Horses, Except
    AR BR UY Mercosu PY applied NCM Description applied applied applied r Final Comments tariff tariff tariff tariff Offer 01012100 Pure-bred horses 0 0 0 0 0 01012900 Lives horses, except pure-bred breeding 2 2 2 2 0 01013000 Asses, pure-bred breeding 4 4 4 4 4 01019000 Asses, except pure-bred breeding 4 4 4 4 4 01022110 Purebred breeding cattle, pregnant or lactating 0 0 0 0 0 01022190 Other pure-bred cattle, for breeding 0 0 0 0 0 Other bovine animals for breeding,pregnant or 01022911 lactating 2 2 2 2 0 01022919 Other bovine animals for breeding 2 2 2 2 4 01022990 Other live catlle 2 2 2 2 0 01023110 Pure-bred breeding buffalo, pregnant or lactating 0 0 0 0 0 01023190 Other pure-bred breeding buffalo 0 0 0 0 0 Other buffalo for breeding, ex. pure-bred or 01023911 pregnant 2 2 2 2 0 Other buffalo for breeding, except pure-bred 01023919 breeding 2 2 2 2 4 01023990 Other buffalos 2 2 2 2 0 01029000 Other live animals of bovine species 0 0 0 0 0 01031000 Pure-bred breedig swines 0 0 0 0 0 01039100 Other live swine, weighing less than 50 kg 2 2 2 2 0 01039200 Other live swine, weighing 50 kg or more 2 2 2 2 0 01041011 Pure-bred breeding, pregnant or lactating, sheep 0 0 0 0 0 01041019 Other pure-bred breeding sheep 0 0 0 0 0 01041090 Others live sheep 2 2 2 2 0 01042010 Pure-bred breeding goats 0 0 0 0 0 01042090 Other live goats 2 2 2 2 0 Fowls spec.gallus domestic.w<=185g pure-bred 01051110 breeding 0 0 0 0 0 Oth.live fowls spec.gall.domest.weig.not more than 01051190 185g 2 2 2 2 0 01051200 Live turkeys, weighing not more than 185g 2 2
    [Show full text]
  • January 2021 Update
    PUBLISHED JULY 08, 2021 OCTOBER/DECEMBER 2020; JANUARY 2021 UPDATE CHANGES TO THE HIGHMARK DRUG FORMULARIES Following is the update to the Highmark Drug Formularies and pharmaceutical management procedures for January 2021. The formularies and pharmaceutical management procedures are updated on a bimonthly basis, and the following changes reflect the decisions made in October, December, and January by our Pharmacy and Therapeutics Committee. These updates are effective on the dates noted throughout this document. Please reference the guide below to navigate this communication: Section I. Highmark Commercial and Healthcare Reform Formularies A. Changes to the Highmark Comprehensive Formulary and the Highmark Comprehensive Healthcare Reform Formulary B. Changes to the Highmark Healthcare Reform Essential Formulary C. Changes to the Highmark Core Formulary D. Changes to the Highmark National Select Formulary E. Updates to the Pharmacy Utilization Management Programs 1. Prior Authorization Program 2. Managed Prescription Drug Coverage (MRxC) Program 3. Formulary Program 4. Quantity Level Limit (QLL) Programs As an added convenience, you can also search our drug formularies and view utilization management policies on the Provider Resource Center (accessible via NaviNet® or our website). Click the Pharmacy Program/Formularies link from the menu on the left. Highmark Blue Cross Blue Shield Delaware is an independent licensee of the Blue Cross and Blue Shield Association. NaviNet is a registered trademark of NaviNet, Inc., which is an independent company that provides secure, web-based portal between providers and health insurance companies. IMPORTANT DRUG SAFETY UPDATES 03/31/2021 – Studies show increased risk of heart rhythm problems with seizure and mental health medicine lamotrigine (Lamictal) in patients with heart disease.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • NINDS Custom Collection II
    ACACETIN ACEBUTOLOL HYDROCHLORIDE ACECLIDINE HYDROCHLORIDE ACEMETACIN ACETAMINOPHEN ACETAMINOSALOL ACETANILIDE ACETARSOL ACETAZOLAMIDE ACETOHYDROXAMIC ACID ACETRIAZOIC ACID ACETYL TYROSINE ETHYL ESTER ACETYLCARNITINE ACETYLCHOLINE ACETYLCYSTEINE ACETYLGLUCOSAMINE ACETYLGLUTAMIC ACID ACETYL-L-LEUCINE ACETYLPHENYLALANINE ACETYLSEROTONIN ACETYLTRYPTOPHAN ACEXAMIC ACID ACIVICIN ACLACINOMYCIN A1 ACONITINE ACRIFLAVINIUM HYDROCHLORIDE ACRISORCIN ACTINONIN ACYCLOVIR ADENOSINE PHOSPHATE ADENOSINE ADRENALINE BITARTRATE AESCULIN AJMALINE AKLAVINE HYDROCHLORIDE ALANYL-dl-LEUCINE ALANYL-dl-PHENYLALANINE ALAPROCLATE ALBENDAZOLE ALBUTEROL ALEXIDINE HYDROCHLORIDE ALLANTOIN ALLOPURINOL ALMOTRIPTAN ALOIN ALPRENOLOL ALTRETAMINE ALVERINE CITRATE AMANTADINE HYDROCHLORIDE AMBROXOL HYDROCHLORIDE AMCINONIDE AMIKACIN SULFATE AMILORIDE HYDROCHLORIDE 3-AMINOBENZAMIDE gamma-AMINOBUTYRIC ACID AMINOCAPROIC ACID N- (2-AMINOETHYL)-4-CHLOROBENZAMIDE (RO-16-6491) AMINOGLUTETHIMIDE AMINOHIPPURIC ACID AMINOHYDROXYBUTYRIC ACID AMINOLEVULINIC ACID HYDROCHLORIDE AMINOPHENAZONE 3-AMINOPROPANESULPHONIC ACID AMINOPYRIDINE 9-AMINO-1,2,3,4-TETRAHYDROACRIDINE HYDROCHLORIDE AMINOTHIAZOLE AMIODARONE HYDROCHLORIDE AMIPRILOSE AMITRIPTYLINE HYDROCHLORIDE AMLODIPINE BESYLATE AMODIAQUINE DIHYDROCHLORIDE AMOXEPINE AMOXICILLIN AMPICILLIN SODIUM AMPROLIUM AMRINONE AMYGDALIN ANABASAMINE HYDROCHLORIDE ANABASINE HYDROCHLORIDE ANCITABINE HYDROCHLORIDE ANDROSTERONE SODIUM SULFATE ANIRACETAM ANISINDIONE ANISODAMINE ANISOMYCIN ANTAZOLINE PHOSPHATE ANTHRALIN ANTIMYCIN A (A1 shown) ANTIPYRINE APHYLLIC
    [Show full text]